Previous 10 | Next 10 |
CAMBRIDGE, Mass. , March 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reaffirmed previously announced plans to host a live conference call...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
CAMBRIDGE, Mass. , Feb. 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that updated data from the Phase 2 PIONEER trial of avapri...
CAMBRIDGE, Mass. , Feb. 19, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in fireside chats at the follow...
Penny stocks might seem like a good investment because you can purchase many shares for a relatively small amount of money. But most of them represent businesses with questionable prospects at best, and owning thousands of shares of a worthless venture means your hard-earned money could vaporize...
Image source: The Motley Fool. Blueprint Medicines (NASDAQ: BPMC) Q4 2019 Earnings Call Feb 13, 2020 , 8:30 a.m. ET Operator Continue reading
Blueprint Medicines Corporation (BPMC) Q4 2019 Results Earnings Conference Call February 13, 2020, 8:30 AM ET Company Participants Kristin Hodous - Senior Manager, Investor Relations Jeff Albers - Chief Executive Officer Dr. Andy Boral - Chief Medical Officer Christy Rossi - Ch...
Blueprint Medicines (NASDAQ: BPMC ): Q4 GAAP EPS of -$1.35 beats by $0.41 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , Feb. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the fourth quart...
Blueprint's (Most Recent) Raise Closed: TBD (proposed pricing on 1/22/20) Pricing: $69.00/share Amount: ~$325 million Over-allotment: TBD Blueprint Medicines ( BPMC ) recently announced a dilutive raise, sending share prices below key moving averages: Blueprint's la...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-07-29 07:15:06 ET Barclays analyst issues EQUAL-WEIGHT recommendation for BPMC on July 29, 2024 05:43AM ET. The previous analyst recommendation was Equal-Weight. BPMC was trading at $112.19 at issue of the analyst recommendation. The overall analyst consensus : BUY....
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $105.00 for BPMC on 2024-07-29 05:43:00. The adjusted price target was set to $105.00. At the time of the announcement, BPMC was trading at $112.19. The overall price target consensus is at $100.7...
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...